The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Cancer Gene Therapy Market Increase Between 2026 And 2030?
The cancer in vitro diagnostics (ivd) market size has experienced significant growth in recent years. This market is projected to expand from $14.32 billion in 2025 to $15.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.0%. The historical growth can be linked to the expansion of hospital diagnostic infrastructure, an increase in biomarker-based testing, the adoption of PCR and immunoassay technologies, an uptick in cancer screening programs, and enhanced laboratory automation.
The cancer in vitro diagnostics (ivd) market size is projected to experience significant expansion in the coming years. It is expected to reach $19.85 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.7%. This forecasted growth can be attributed to the rising demand for personalized oncology diagnostics, increasing investments in genomic sequencing, the broadening of point-of-care cancer testing, the expanding integration of cloud-based diagnostic platforms, and a heightened focus on precision medicine. Noteworthy trends during the forecast period include the increasing adoption of molecular and genomic cancer testing, a rise in the use of companion diagnostics, the growing integration of AI-driven data analysis, the expansion of liquid biopsy applications, and an enhanced emphasis on early cancer detection.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp
What Market Drivers Are Helping Shape The Cancer Gene Therapy Market Expansion?
The escalating occurrence of cancer is projected to boost the expansion of the cancer in vitro diagnostics (IVD) market moving forward. Cancer describes the uncontrolled proliferation and spread of abnormal cells within the body, which can invade neighboring tissues and form tumors. The rising incidence of cancer is attributed to an aging global population, where longer life expectancies and decreased mortality from infectious diseases result in a larger elderly demographic more vulnerable to developing cancer. Cancer in vitro diagnostics (IVD) assists in managing cancer by enabling early and precise detection, continuous monitoring, and effective management of the disease through laboratory tests conducted on patient samples, thereby allowing timely treatment decisions and enhancing patient outcomes. For instance, in January 2023, the American Cancer Society, a US-based professional organization dedicated to eliminating cancer, reported that 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023 in the United States. Therefore, the growing incidence of cancer is propelling the growth of the cancer in vitro diagnostics (IVD) market.
How Is Segment Classification Applied In The Cancer Gene Therapy Market?
The cancer gene therapy market covered in this report is segmented –
1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer
2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications
3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types
4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users
Subsegments:
1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy
2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)
3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer
What Trends Are Influencing The Future Of The Cancer Gene Therapy Market?
Leading firms within the cancer in vitro diagnostics market are prioritizing advancements in cancer screening, particularly through methods like blood-based colorectal cancer (CRC) screening, aimed at offering accessible, non-intrusive, and precise early detection of colorectal cancer. This type of CRC screening involves identifying molecular changes linked to cancer, specifically circulating tumor DNA (ctDNA), present in a patient’s blood sample to diagnose colorectal cancer in individuals with an average risk profile. An illustrative example is from July 2024, when Guardant Health, Inc., a precision oncology company based in the U.S., secured approval from the U.S. Food and Drug Administration (FDA) for its Guardant Shield blood test, positioning it as a primary method for colorectal cancer screening. This test operates by examining a blood specimen for particular ctDNA methylation patterns and additional markers originating from tumors. Its distinct characteristics encompass noninvasive sample collection, superior analytical precision, and seamless integration into clinical protocols for initial screening. Its utility extends to the early identification of colorectal cancer in average-risk adults. Advantages derived from its use include enhanced patient compliance, quicker detection of malignancies, a possible decrease in diagnoses at advanced stages, and qualification for Medicare reimbursement, which broadens screening accessibility for a wider population.
Which Companies Form The Competitive Landscape Of The Cancer Gene Therapy Market?
Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.
Access The Complete Cancer Gene Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report
Which Area Represents The Largest Portion Of The Cancer Gene Therapy Market?
North America was the largest region in the cancer gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Cancer Gene Therapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp
Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2026, By The Business Research Company
Cyclin Dependent Kinase Cdk 4 Or 6 Inhibitor Drugs Global Market Report 2026
Tyrosine Kinase Inhibitors Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report
Janus Kinase Jak Inhibitors Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model